Cryosite Ltd (CTE) - Total Assets
Based on the latest financial reports, Cryosite Ltd (CTE) holds total assets worth AU$26.55 Million AUD (≈ $18.78 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cryosite Ltd - Total Assets Trend (2001–2025)
This chart illustrates how Cryosite Ltd's total assets have evolved over time, based on quarterly financial data. Also see Cryosite Ltd stock valuation for the company's overall valuation and market capitalisation.
Cryosite Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Cryosite Ltd's total assets of AU$26.55 Million consist of 45.6% current assets and 54.4% non-current assets. Review Cryosite Ltd debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 26.0% |
| Accounts Receivable | AU$2.29 Million | 11.7% |
| Inventory | AU$43.00K | 0.2% |
| Property, Plant & Equipment | AU$1.42 Million | 7.3% |
| Intangible Assets | AU$32.00K | 0.2% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Cryosite Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CTE share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cryosite Ltd's current assets represent 45.6% of total assets in 2025, a decrease from 70.4% in 2001.
- Cash Position: Cash and equivalents constituted 26.0% of total assets in 2025, down from 68.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 11.7% of total assets.
Cryosite Ltd Competitors by Total Assets
Key competitors of Cryosite Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
LONZA GROUP UNSP.ADR 1/10
F:LO3A
|
Germany | €17.91 Billion |
|
Lumibird SA
PA:LBIRD
|
France | €428.90 Million |
|
INTERGRATED DIA.H DL 025
F:8I8
|
Germany | €6.77 Billion |
|
Bcal Diagnostics Ltd
AU:BDX
|
Australia | AU$7.66 Million |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
USA | $7.94 Million |
|
IZOTROPIC CORP.
F:1R3
|
Germany | €439.78K |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
Cryosite Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.49 | 1.78 | 1.62 |
| Quick Ratio | 0.48 | 1.77 | 1.61 |
| Cash Ratio | 0.00 | 0.00 | 1.27 |
| Working Capital | AU$-5.73 Million | AU$3.40 Million | AU$2.11 Million |
Cryosite Ltd - Advanced Valuation Insights
This section examines the relationship between Cryosite Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.23 |
| Latest Market Cap to Assets Ratio | 2.08 |
| Asset Growth Rate (YoY) | -1.3% |
| Total Assets | AU$19.46 Million |
| Market Capitalization | $40.58 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cryosite Ltd's assets at a significant premium (2.08x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Cryosite Ltd's assets decreased by 1.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Cryosite Ltd (2001–2025)
The table below shows the annual total assets of Cryosite Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$19.46 Million ≈ $13.77 Million |
-1.26% |
| 2024-06-30 | AU$19.71 Million ≈ $13.95 Million |
-12.96% |
| 2023-06-30 | AU$22.65 Million ≈ $16.02 Million |
+5.32% |
| 2022-06-30 | AU$21.50 Million ≈ $15.21 Million |
-2.23% |
| 2021-06-30 | AU$21.99 Million ≈ $15.56 Million |
-6.42% |
| 2020-06-30 | AU$23.50 Million ≈ $16.63 Million |
+1.42% |
| 2019-06-30 | AU$23.17 Million ≈ $16.40 Million |
+199.24% |
| 2018-06-30 | AU$7.74 Million ≈ $5.48 Million |
-21.20% |
| 2017-06-30 | AU$9.83 Million ≈ $6.95 Million |
+1.76% |
| 2016-06-30 | AU$9.66 Million ≈ $6.83 Million |
+5.86% |
| 2015-06-30 | AU$9.12 Million ≈ $6.45 Million |
-18.49% |
| 2014-06-30 | AU$11.19 Million ≈ $7.92 Million |
-1.49% |
| 2013-06-30 | AU$11.36 Million ≈ $8.04 Million |
+16.29% |
| 2012-06-30 | AU$9.77 Million ≈ $6.91 Million |
+13.28% |
| 2011-06-30 | AU$8.63 Million ≈ $6.10 Million |
+12.27% |
| 2010-06-30 | AU$7.68 Million ≈ $5.44 Million |
+4.46% |
| 2009-06-30 | AU$7.35 Million ≈ $5.20 Million |
+1.46% |
| 2008-06-30 | AU$7.25 Million ≈ $5.13 Million |
+13.30% |
| 2007-06-30 | AU$6.40 Million ≈ $4.53 Million |
+25.10% |
| 2006-06-30 | AU$5.11 Million ≈ $3.62 Million |
+9.71% |
| 2005-06-30 | AU$4.66 Million ≈ $3.30 Million |
+5.87% |
| 2004-06-30 | AU$4.40 Million ≈ $3.12 Million |
+24.92% |
| 2003-06-30 | AU$3.52 Million ≈ $2.49 Million |
-19.14% |
| 2002-06-30 | AU$4.36 Million ≈ $3.08 Million |
+7.68% |
| 2001-06-30 | AU$4.05 Million ≈ $2.86 Million |
-- |
About Cryosite Ltd
Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial … Read more